Recent developments include FDA regulatory updates, clinical data releases, insider buying activity, and corporate communications highlighting clinical and regulatory progress.

• In August 2025, enVVeno received a non-approvable letter from the FDA for the VenoValve PMA application, leading to a decline in shares [N1].
• In June 2025, the company revealed promising 2-year clinical data from the VenoValve pivotal trial, which was well received by clinicians [N2].
• In March 2025, enVVeno awaited FDA decisions on its products amid broader industry news [N3].
• In January 2025, insider buying was reported, including a director purchasing 81,433 shares, indicating insider confidence [N4][N5].
• In November 2024, enVVeno submitted the VenoValve PMA application to the FDA and completed the application process [N7][N8].
• In November 2024, the company launched a recap website highlighting participation in the VEITH Symposium, emphasizing clinical engagement [N6].
• In October 2024, enVVeno reported Q3 EPS of -$0.35 compared to -$0.45 the prior year and stated it expects capital to fund operations through several milestones [N9][N10].

The enVVe System represents a novel, minimally invasive treatment for severe CVI, a condition with significant unmet medical need and no approved replacement venous valves. Positive clinical data from the VenoValve pivotal study has been well received by clinicians, indicating strong interest in the technology. enVVeno’s proprietary manufacturing capabilities and patent portfolio provide a foundation for competitive differentiation. Insider buying activity and recent capital raises suggest confidence in the company’s development strategy. If regulatory milestones are met, the enVVe System could address a large patient population and establish a new standard of care.

The company’s initial product, VenoValve, failed to obtain FDA approval, highlighting regulatory challenges. The enVVe System remains in pre-clinical stages with pivotal trials yet to commence, exposing enVVeno to clinical and regulatory risks. The company has no current revenues and has incurred significant losses, relying on capital raises to fund operations. Supply chain constraints, manufacturing scale-up challenges, and competition from other medical device companies add to execution risks. Failure to secure FDA approval or adequate funding could materially impair business prospects.

enVVeno’s competitive strengths include proprietary processing and manufacturing methodologies for biologic tissue devices, an ISO 13485-2016 certified manufacturing facility dedicated to Class III implantable medical devices, and a portfolio of 42 patents worldwide protecting its venous valve technologies. The company benefits from experienced senior management and advisory boards with FDA approval expertise. The enVVe System’s minimally invasive, transcatheter delivery approach addresses unmet clinical needs in severe CVI treatment, with no currently approved alternatives, potentially positioning enVVeno uniquely in this niche market. However, the company’s moat is contingent on successful regulatory approvals and commercialization execution.

• Regulatory Approval Risk: The FDA has not approved any of enVVeno’s products to date. The VenoValve received a non-approvable letter, and the enVVe System requires IDE and PMA approvals, which involve lengthy and uncertain processes.
• Capital and Liquidity Risk: enVVeno has incurred significant losses and depends on raising additional capital to fund clinical trials and operations. Failure to secure funding could delay or halt development.
• Clinical Development Risk: The enVVe System is in pre-clinical stages with pivotal trials planned. Clinical trial outcomes may not demonstrate safety or efficacy sufficient for approval.
• Manufacturing and Supply Chain Risk: The company relies on a single manufacturing facility and limited suppliers. Disruptions or inability to scale production could delay development and commercialization.
• Market Adoption Risk: Even if approved, the enVVe System must achieve market acceptance among physicians and payors, which may be hindered by competition or reimbursement challenges.

• enVVeno Medical Corp is a medical device company focused on developing bioprosthetic tissue-based solutions for venous disease treatment, specifically targeting severe Chronic Venous Insufficiency (CVI) of the deep venous system of the leg [S1].
• The company initially developed the VenoValve, a first-in-class surgical replacement venous valve, which received a not-approvable letter from the FDA in August 2025 and an unsuccessful appeal thereafter [S1].
• Following the VenoValve FDA outcome, enVVeno is focusing on the enVVe System, a next-generation, non-surgical, transcatheter-based replacement venous valve designed to treat severe CVI [S1].
• The enVVe System includes the enVVe Valve, Delivery System, Nose Cone, Delivery System Accessories, and Crimping System, and has completed pre-clinical testing with ongoing FDA discussions regarding a pivotal trial [S1].
• There are currently no FDA-approved surgical or non-surgical replacement venous valves, and no effective treatments for deep venous CVI caused by incompetent valves [S1].
• enVVeno operates a 14,507 sq. ft. ISO 13485-2016 certified manufacturing facility in Irvine, California, for design, development, and manufacturing of tissue-based implantable medical devices [S1].
• The company has 33 full-time employees as of March 2026 and has attracted senior executives experienced in FDA approvals and CE marking [S1].
• enVVeno holds 42 patents worldwide related to the VenoValve and enVVe System, including 9 granted by the USPTO [S1].
• The company has incurred significant operating losses, with a net loss of $19.472 million for the fiscal year ended December 31, 2025, and a basic and diluted EPS of -$33.06 per share [S1].
• As of December 31, 2025, enVVeno had cash and cash equivalents of $3.065 million, short-term investments of $25.147 million, current assets of $28.826 million, and current liabilities of $2.122 million, resulting in a current ratio of 13.58 and a cash ratio of 13.3, indicating strong liquidity [S1].
• The company has no revenues reported and is not currently generating revenue from operations [S1].
• enVVeno has experienced negative operating cash flows since inception and funds operations primarily through equity and convertible/non-convertible notes [S1].
• The company submitted a PMA application for the VenoValve in November 2024 but received a non-approvable letter from the FDA in August 2025 [S1].
• enVVeno has elected to forego approval and commercialization efforts for the VenoValve outside the U.S. and is focusing resources on the enVVe System [S1].
• The enVVe System is designed to address prior FDA concerns related to surgical venous valves by offering a minimally invasive, catheter-based approach, potentially broadening physician adoption [S1].
• The company has begun discussions with the FDA regarding the enVVe pivotal trial, which it plans to initiate in 2026 [S1].
• Clinical data from the SAVVE pivotal study of the VenoValve has been presented globally and received positive reception from clinicians, highlighting the unmet need for replacement venous valves [S1].
• The company faces regulatory risks including FDA approval uncertainties, potential delays, and the need for IDE approval before human trials for enVVe [S1].
• enVVeno's business risks include the need for additional capital to fund operations and development, potential supply chain constraints, and competition in the medical device market [S1].
• Recent news highlights include the FDA's unfavorable review outcome for VenoValve in August 2025, promising 2-year clinical data for VenoValve in June 2025, and ongoing FDA decision anticipation in early 2025 [N1][N2][N3].
• Insider buying activity was reported in early 2025, including a director purchasing 81,433 shares [N4][N5].
• The company completed the VenoValve PMA application in late 2024 and submitted it to the FDA in November 2024 [N7][N8].
• enVVeno launched a recap website highlighting participation in the VEITH Symposium in November 2024 [N6].
• The company reported Q3 2024 EPS of -$0.35 compared to -$0.45 the prior year and expects capital to fund operations through several milestones [N9][N10].